Detalles de la búsqueda
1.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC Cancer
; 23(1): 710, 2023 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37516867
2.
Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study).
Gastrointest Endosc
; 98(3): 392-399.e1, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37059368
3.
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Int J Cancer
; 151(11): 1978-1988, 2022 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35833561
4.
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Eur J Cancer
; 162: 138-147, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34995900
5.
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
Ther Adv Med Oncol
; 12: 1758835920975356, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33329760
Resultados
1 -
5
de 5
1
Próxima >
>>